Skip to main content
. 2022 Mar 28;27(Suppl 1):S9–S10. doi: 10.1093/oncolo/oyac016

Table 3.

Grade 3-4 adverse events in patients with ER-positive metastatic breast cancer

Adverse event Palbociclib plus AI (n = 84) Palbociclib plus fulvestrant (n = 88)
Leukopenia
 Grade 3 6.0% 6.8%
Neutropenia
 Grade 3 34.5% 36.4%
 Grade 4 2.4% 0%
Anemia
 Grade 3 2.4% 0%
Thrombocytopenia
 Grade 3 1.2% 2.3%
Nausea
 Grade 3 1.2% 0%
Pneumopathy
 Grade 3 3.6% 0%
Pain
 Grade 3 1.2% 4.5%
Other
 Grade 3 6.0% 0%
 Grade 4 0% 1.1%